The understanding of cancer's genetic basis has revolutionized oncology, paving the way for significant advancements in personalized medicine.  Recent breakthroughs in next-generation sequencing technologies have enabled comprehensive genomic profiling of tumors, identifying specific driver mutations and revealing the intricate landscape of somatic alterations. This detailed genetic characterization allows for the stratification of patients into more homogeneous subgroups based on their unique tumor profiles, moving beyond traditional histological classifications.  This precision oncology approach facilitates the selection of targeted therapies, such as tyrosine kinase inhibitors (TKIs) for specific mutations in EGFR or ALK genes in lung cancer, or immunotherapy tailored to the presence of neoantigens revealed through genomic analysis.  Furthermore, liquid biopsies, which analyze circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), provide minimally invasive means for continuous monitoring of disease progression, treatment response, and the emergence of resistance mutations, enabling timely adjustments to therapeutic strategies. While challenges remain, including the identification of actionable mutations and addressing treatment resistance, the integration of genomic information into clinical decision-making is steadily transforming cancer treatment from a one-size-fits-all approach to a more personalized and effective paradigm.